Targeting glioma stem cells through combined BMI1 and EZH2 inhibition

Nat Med. 2017 Nov;23(11):1352-1361. doi: 10.1038/nm.4415. Epub 2017 Oct 9.

Abstract

Glioblastomas are lethal cancers defined by angiogenesis and pseudopalisading necrosis. Here, we demonstrate that these histological features are associated with distinct transcriptional programs, with vascular regions showing a proneural profile, and hypoxic regions showing a mesenchymal pattern. As these regions harbor glioma stem cells (GSCs), we investigated the epigenetic regulation of these two niches. Proneural, perivascular GSCs activated EZH2, whereas mesenchymal GSCs in hypoxic regions expressed BMI1 protein, which promoted cellular survival under stress due to downregulation of the E3 ligase RNF144A. Using both genetic and pharmacologic inhibition, we found that proneural GSCs are preferentially sensitive to EZH2 disruption, whereas mesenchymal GSCs are more sensitive to BMI1 inhibition. Given that glioblastomas contain both proneural and mesenchymal GSCs, combined EZH2 and BMI1 targeting proved more effective than either agent alone both in culture and in vivo, suggesting that strategies that simultaneously target multiple epigenetic regulators within glioblastomas may be effective in overcoming therapy resistance caused by intratumoral heterogeneity.

MeSH terms

  • Animals
  • Brain Neoplasms / pathology*
  • Enhancer of Zeste Homolog 2 Protein / antagonists & inhibitors*
  • Epigenesis, Genetic
  • Glioblastoma / pathology*
  • Humans
  • Mice
  • Neoplastic Stem Cells / drug effects*
  • Polycomb Repressive Complex 1 / antagonists & inhibitors*
  • Reverse Transcriptase Polymerase Chain Reaction

Substances

  • BMI1 protein, human
  • EZH2 protein, human
  • Enhancer of Zeste Homolog 2 Protein
  • Polycomb Repressive Complex 1